Candel Therapeutics Reports $8.9 Million Net Loss Amid Increased Operating Expenses

Candel Therapeutics, Inc. reported a significant financial downturn in its latest quarterly results, with a net loss of $8.9 million for the three months ending March 31, 2026, compared to a net income of $7.4 million during the same period in 2025. This shift is attributed to a substantial increase in operating expenses, which rose to $16.3 million from $8.1 million year-over-year. The increase in expenses was primarily driven by heightened research and development costs, which surged to $9.8 million from $4.0 million, reflecting intensified clinical trial activities and associated regulatory costs for its lead product candidate, aglatimagene.

The company’s cash and cash equivalents saw a notable increase, reaching $194.8 million as of March 31, 2026, up from $119.7 million at the end of 2025. This increase was largely due to a successful public offering completed in February 2026, which generated approximately $93.5 million in net proceeds after expenses. Candel's total assets also rose to $201.9 million, compared to $125.2 million at the end of the previous fiscal year, indicating a strengthened financial position despite the operational losses.

Candel Therapeutics has made strategic advancements in its clinical pipeline, particularly with aglatimagene, which is currently undergoing pivotal phase 3 trials for localized prostate cancer. The company has received Fast Track Designation from the FDA for this treatment, and recent clinical data has shown promising results, including a statistically significant improvement in disease-free survival rates. Additionally, the company is preparing for a potential Biologics License Application (BLA) submission later in 2026, which could further enhance its market position.

Operationally, Candel has expanded its employee base, with a headcount increase reflecting its growth strategy and ongoing clinical development efforts. The company has also entered into a significant purchase agreement with RTW Investments, which could provide $100 million upon FDA approval of aglatimagene, further bolstering its financial resources. However, Candel continues to face challenges typical of the biotechnology sector, including the need for substantial ongoing funding to support its research and development activities, as well as the inherent risks associated with clinical trials.

Looking ahead, Candel Therapeutics anticipates continued operating losses as it advances its clinical programs and prepares for commercialization efforts. The company expects its existing cash reserves will sustain operations into the first quarter of 2028, but it acknowledges the necessity of securing additional capital to support its long-term growth and development objectives.